SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-20-007978
Filing Date
2020-05-18
Accepted
2020-05-18 16:43:17
Documents
14
Period of Report
2020-05-18
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-kisanchendepartu.htm   iXBRL 8-K 53163
  Complete submission text file 0001628280-20-007978.txt   204760

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrtx-20200518.xsd EX-101.SCH 4426
3 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrtx-20200518_cal.xml EX-101.CAL 608
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrtx-20200518_def.xml EX-101.DEF 1458
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrtx-20200518_lab.xml EX-101.LAB 28353
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrtx-20200518_pre.xml EX-101.PRE 14626
12 EXTRACTED XBRL INSTANCE DOCUMENT form8-kisanchendepartu_htm.xml XML 4731
Mailing Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35921 | Film No.: 20890235
SIC: 2834 Pharmaceutical Preparations